Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Reduced monthly costs for uninsured patients still amount to around $500. That can put the drugs out of reach for many.

Shares of Novo Nordisk (NYSE:NVO) rose 1% following news that the company has submitted an application to the European Medicines Agency (EMA) to approve a higher dose of its obesity treatment, Wegovy.

Kate Farms has launched high-protein plant-based shakes to tackle "critical nutrition gaps" from GLP-1 use, its first product ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Stocks that pay dividends tend to outperform ones that don't. Consensus price targets for Novo Nordisk suggest the stock can ...

The lack of details about which countries are involved and which companies will be impacted as a result of the new trade deal ...

WeightWatchers announces Dr. Kim Boyd as its new chief medical officer and unveils a program to support women through ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...

As summer began and temperatures rose in June, so too did TV ad spending for Novo Nordisk’s Wegovy. | As summer began and ...